BioCentury
ARTICLE | Clinical News

OvaRex MAb: Phase II comparability data; Phase III

May 12, 2003 7:00 AM UTC

In a U.S. Phase II study in 26 patients, OvaRex derived from mouse ascites fluid showed no significant pharmacokinetic, immunologic or safety differences compared to OvaRex manufactured using a protei...